GenSci120
/ GeneScience
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 07, 2025
Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
June 27, 2025
Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
February 26, 2025
A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.
(clinicaltrials.gov)
- P1 | N=56 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology
February 16, 2025
A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.
(clinicaltrials.gov)
- P1 | N=56 | Not yet recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
New P1 trial • Immunology • PD-1
1 to 4
Of
4
Go to page
1